FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond - Pai‐Scherf, Lee; Blumenthal, Gideon M.; Li, Hongshan; Subramaniam, Sriram; Mishra‐Kalyani, Pallavi S.; He, Kun; Zhao, Hong; Yu, Jingyu; Paciga, Mark; Goldberg, Kirsten B.; McKee, Amy E.; Keegan, Patricia; et al. (The oncologist (Dayton, Ohio), 2017)
Keywords: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; B7-H1 Antigen - genetics; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Disease Progression; Drug Approval; EGFR protein, Human; Gene Expression Regulation, Neoplastic - drug effects; Humans; Middle Aged; Non‐small cell lung cancer; Pembrolizumab; Receptor, Epidermal Growth Factor - genetics; Regulatory Issues: FDA; Taxoids - administration & dosage; United States; United States Food and Drug Administration; Pembrolizumab; EGFR protein, Human; Non‐small cell lung cancer; United States Food and Drug Administration